First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced EGFR mutation positive NSCLC with CNS metastases.
Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-naïve advanced NSCLC and documented intracranial disease will be enrolled.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100021
- China site
-
Beijing, China, 100071
- China site
-
Beijing, China, 100142
- China site
-
Beijing, China, 100730
- China site
-
Chongqing, China, 400030
- China site
-
Chongqing, China, 400042
- China site
-
Shanghai, China, 200030
- China site
-
Shanghai, China, 200032
- China site
-
Tianjin, China, 300052
- China site
-
-
Anhui
-
Hefei, Anhui, China, 230001
- China site
-
-
China
-
Chongqing, China, China, 400037
- China site
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- China site
-
Xiamen, Fujian, China, 361003
- China site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- China site
-
Guangzhou, Guangdong, China, 510180
- China site
-
-
Heilongjiang
-
Haerbin, Heilongjiang, China, 150081
- China site
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- China site
-
Zhengzhou, Henan, China, 450052
- China site
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- China site
-
Wuhan, Hubei, China, 430030
- China site
-
Wuhan, Hubei, China, 430079
- China site
-
Yichang, Hubei, China, 443003
- China site
-
-
Hunan
-
Changsha, Hunan, China, 410013
- China site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- China site
-
Nanjing, Jiangsu, China, 210009
- China site
-
Suzhou, Jiangsu, China, 215004
- China site
-
Wuxi, Jiangsu, China, 214062
- China site
-
Xuzhou, Jiangsu, China, 221002
- China site
-
Yangzhou, Jiangsu, China, 225001
- China site
-
-
Jilin
-
Changchun, Jilin, China, 130012
- China site
-
Changchun, Jilin, China, 130021
- China site
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- China site
-
-
Shandong
-
Jinan, Shandong, China, 250117
- China site 0123
-
Linyi, Shandong, China, 276000
- China site
-
Weifang, Shandong, China, 261000
- China site
-
Yantai, Shandong, China, 264000
- China site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- China site
-
-
Yunnan
-
Kunming, Yunnan, China, 650118
- China site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- China site
-
Hangzhou, Zhejiang, China, 310022
- China site
-
Hangzhou, Zhejiang, China, 311100
- China site
-
-
-
-
-
Singapore, Singapore, 308433
- Singapore site
-
-
-
-
-
Daegu, South Korea, 42415
- Korea site
-
Gyeonggi-do, South Korea, 16247
- Korea site
-
Gyeongsang, South Korea, 52727
- Korea site
-
Incheon, South Korea, 21565
- Korea site
-
Jungbuk, South Korea, 28644
- Korea site
-
Seoul, South Korea, 03080
- Korea site
-
Seoul, South Korea, 05368
- Korea site
-
Seoul, South Korea, 06351
- Korea site
-
Seoul, South Korea, 06591
- Korea site
-
Seoul, South Korea, 07061
- Korea site
-
Suwon, South Korea, 16499
- Korea site
-
Ulsan, South Korea, 44033
- Korea site
-
-
-
-
-
Taichung, Taiwan, 407
- Taiwan site
-
Tainan City, Taiwan, 704
- Taiwan site
-
Taipei, Taiwan, 100
- Taiwan site
-
Taoyuan District, Taiwan, 333
- Taiwan site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Properly completed patient informed consent
- Male or female aged at least 18 years
- Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR mutations including L858R and/or Exon19Del. EGFR mutation status will be determined by local or central laboratory testing on tumour tissue or plasma utilizing a validated methodology which has been approved by the regulatory authority.
- No prior treatment with chemotherapy, EGFR-TKIs, or biological therapies that are considered first line treatment for advanced NSCLC.
- All patients must have a documented diagnosis of advanced (Stage IV) NSCLC with Magnetic Resonance Imaging (MRI) documented CNS metastases that include brain metastases (BM). BM + patients with co- existent leptomeningeal involvement are eligible for the study.
- Eligible patients are not candidates for definitive surgical resection or radiation of all lesions in the opinion of the treating physician.
- All patients must be stable without any systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.
- Patients may have prior placement of a properly functioning CNS shunt or Ommaya reservoir.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks.
- Women of child-bearing potential and male subjects shall agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All women of child-bearing potential must have a negative blood pregnancy test at screening.
- (a) For Patients with measurable CNS lesions must have AT LEAST ONE site of CNS lesion, which was not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter by MRI and which is suitable for accurate repeated measurements. Measurable extracranial disease is not required. (b) For Patients with non-measurable CNS lesions must have AT LEAST ONE extracranial lesion, which has not been previously irradiated, within the screening period that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) by CT/MRI and are suitable for accurate repeated measurement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AZD3759 Group
AZD3759 group will receive a 200 mg twice daily dose of AZD3759
|
AZD3759 200mg PO BID.
|
|
Active Comparator: Erlotinib or Gefitinib Group
SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
|
SoC EGFRTKI Erlotinib 150 mg PO Q.D
Other Names:
SoC EGFRTKI Gefitinib 250 mg PO Q.D
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS assessed by Blinded Independent Central Radiological
Time Frame: 48 months
|
To assess if first line treatment with AZD3759 results in significant PFS efficacy compared to Gefitinib or Erlotinib as determined by Blinded Independent Central Radiological (BICR) review using RECIST 1.1.
|
48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS assess by investigator
Time Frame: 48 months
|
Investigator assessment of PFS using RECIST 1.1
|
48 months
|
|
Intracranial PFS (iPFS) assessed by investigator
Time Frame: 48 months
|
Intracranial PFS (iPFS) assessed by investigator using RECIST 1.1
|
48 months
|
|
Intracranial PFS (iPFS) assessed by BICR
Time Frame: 48 months
|
Intracranial PFS (iPFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1
|
48 months
|
|
Extracranial PFS (ePFS) assessed by investigator
Time Frame: 48 months
|
Extracranial PFS (ePFS) assessed by investigator using RECIST 1.1
|
48 months
|
|
Extracranial PFS (ePFS) assessed by BICR
Time Frame: 48 months
|
Extracranial PFS (ePFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1
|
48 months
|
|
Objective Response Rate (ORR) assessed by investigator using RECIST 1.1
Time Frame: 48 months
|
Objective Response Rate (ORR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1
|
48 months
|
|
Disease Control Rate (DCR) assessed by investigator using RECIST 1.1
Time Frame: 48 months
|
Disease Control Rate (DCR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1
|
48 months
|
|
Duration of Response (DoR) assessed by investigator using RECIST 1.1
Time Frame: 48 months
|
Duration of Response (DoR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1
|
48 months
|
|
Overall ORR assessed by investigator using RECIST 1.1
Time Frame: 48 months
|
Overall ORR assessed by investigator using RECIST 1.1
|
48 months
|
|
Overall DCR assessed by investigator using RECIST 1.1
Time Frame: 48 months
|
Overall DCR assessed by investigator using RECIST 1.1
|
48 months
|
|
Overall DoR assessed by investigator using RECIST 1.1
Time Frame: 48 months
|
Overall DoR assessed by investigator using RECIST 1.1
|
48 months
|
|
ORR for Intracranial lesions assessed by investigator using RANO-BM
Time Frame: 48 months
|
ORR for Intracranial lesions assessed by investigator using RANO-BM
|
48 months
|
|
DCR for Intracranial lesions assessed by investigator using RANO-BM
Time Frame: 48 months
|
DCR for Intracranial lesions assessed by investigator using RANO-BM
|
48 months
|
|
DoR for Intracranial lesions assessed by investigator using RANO-BM
Time Frame: 48 months
|
DoR for Intracranial lesions assessed by investigator using RANO-BM
|
48 months
|
|
Overall Survival
Time Frame: 48 months
|
Overall Survival
|
48 months
|
|
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).
Time Frame: 48 months
|
The 30-items questionnaire measures cancer patients' functioning and symptoms.
The scale range of EORTC QLQ-C30 is 30-126.
Lower values represent a better outcome.
|
48 months
|
|
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire BN20 (EORTC QLQ-BN20).
Time Frame: 48 months
|
The 20-items questionnaire was used among brain cancer patients.
The scale range of EORTC BN20 is 20-80.
Lower values represent a better outcome.
|
48 months
|
|
Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)
Time Frame: 48 months
|
Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)
|
48 months
|
|
Neurological function improvement rate assessed by RANO-BM criteria
Time Frame: 48 months
|
Neurological function improvement rate assessed by RANO-BM criteria
|
48 months
|
|
Number of participants with treatment-related Adverse Events as assessed by CTCAE v5.0
Time Frame: 48 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
48 months
|
|
Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0
Time Frame: 48 months
|
Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0
|
48 months
|
|
Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0
Time Frame: 48 months
|
Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0
|
48 months
|
|
Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0
Time Frame: 48 months
|
Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0
|
48 months
|
|
Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0
Time Frame: 48 months
|
Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0
|
48 months
|
|
Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.
Time Frame: 48 months
|
Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.
|
48 months
|
|
Systolic and Diastolic Blood Pressure assessed during the study period.
Time Frame: 48 months
|
Systolic and Diastolic Blood Pressure assessed during the study period.
|
48 months
|
|
Pulse rate assessed during the study period.
Time Frame: 48 months
|
Pulse rate to assessed during the study period.
|
48 months
|
|
Body temperature assessed during the study period.
Time Frame: 48 months
|
Body temperature assessed during the study period.
|
48 months
|
|
PFS assess by BICR
Time Frame: 48 months
|
Blinded Independent Central Radiological (BICR) assessment of PFS using modified RECIST 1.1.
|
48 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pop-PK analysis
Time Frame: 48 months
|
Population pharmacokinetic analysis
|
48 months
|
|
Exposure-Response analysis
Time Frame: 48 months
|
explore the correlation in exposure and efficacy, exposure and safety in the Study
|
48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yilong Wu, M.D., Guangdong Provincial People's Hospital
- Principal Investigator: Myung-Ju Ahn, M.D., Samsung Medical Center, Sungkyunkwan University School of Medicine
- Principal Investigator: Jie Wang, M.D., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Principal Investigator: Qing Zhou, M.D., Guangdong Provincial People's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Nervous System Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Central Nervous System Neoplasms
- Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Respiratory Tract Diseases
- Brain Neoplasms
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Quinazolines
- Erlotinib Hydrochloride
- Gefitinib
- AZD3759
Other Study ID Numbers
Other Study ID Numbers
- AZD3759-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.